Page last updated: 2024-10-21

tacrine and Cognition Disorders

tacrine has been researched along with Cognition Disorders in 39 studies

Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.
tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.

Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.

Research Excerpts

ExcerptRelevanceReference
" This article reviews basic approaches in pharmacoeconomics; current knowledge of costs related to dementia; assessment of quality of life in patients with cognitive impairment; models of relationships among degree of cognitive impairment, caregiver burden, and health care utilization; existing pharmacoeconomic guidelines for drug studies; pharmacoeconomic studies of tacrine, a drug used in Alzheimer disease; and further work needed to advance the critical area of pharmacoeconomic studies in dementia."3.69Pharmacoeconomics of dementia. ( Whitehouse, PJ, 1997)
"Factor analysis methodology applied to Alzheimer's Disease Assessment Scale (ADAS) subtest profiles for patients in two large-scale clinical trials of the antidementia drug tacrine yielded three oblique factors interpreted as dysfunctions in memory, language, and praxis."2.68Cardinal features of cognitive dysfunction in Alzheimer's disease: a factor-analytic study of the Alzheimer's Disease Assessment Scale. ( Gracon, SI; Overall, JE; Srirama, MK; Talwalker, S, 1996)
"Men and women with probable Alzheimer's disease, at least 50 years old, mildly to moderately impaired, without other significant medical conditions."2.67A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. ( Dolan-Ureno, J; Farlow, M; Gracon, SI; Hershey, LA; Lewis, KW; Sadowsky, CH, 1992)
"The rapid growth of the world's Alzheimer's disease (AD) population has resulted in a tremendous financial burden on society, a situation exacerbated by the fact that the funding of health and social services faces increasing restrictions in the coming years."2.40An economic perspective on Alzheimer's disease. ( Trabucchi, M, 1999)
"Developing treatment guidelines for Alzheimer's disease and other dementias depends primarily on a literature review."2.39Developing treatment guidelines for Alzheimer's disease and other dementias. ( Rabins, PV, 1996)
" Chronic administration of B3C for 21 days prevented the memory impairments of the AD model mice in a dose-dependent manner."1.43Bis(propyl)-cognitin Prevents β-amyloid-induced Memory Deficits as Well as Synaptic Formation and Plasticity Impairments via the Activation of PI3-K Pathway. ( An, P; Chen, X; Feng, C; Han, Y; Huang, M; Jiang, L; Wang, Q; Wang, Y; Wei, X; Xu, S, 2016)
"Tacrine was given in doses between 80 and to 160 mg daily for 13-31 months."1.30Long-term tacrine treatment in three mild Alzheimer patients: effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities. ( Amberla, K; Andersson, J; Hartvig, P; Hellström-Lindahl, E; Johansson, M; Långström, B; Lilja, A; Lundqvist, H; Nordberg, A; Shigeta, M; Viitanen, M; Winblad, B, 1998)
"Treatments in Alzheimer's disease include treatment of cognitive impairment and behavioral manifestations (agitation, depression, anxiety, delusions)."1.30[Drug therapy strategies in Alzheimer's disease]. ( Lacomblez, L, 1998)
"According to the cholinergic theory of Alzheimer's disease, the cognitive failure depends on a deficit in acetylcholine."1.29[Use of cholinesterase inhibitors in Alzheimer disease]. ( Sampalmieri, M; Servi, M; Troiani, MP, 1993)

Research

Studies (39)

TimeframeStudies, this research(%)All Research%
pre-19901 (2.56)18.7374
1990's19 (48.72)18.2507
2000's11 (28.21)29.6817
2010's8 (20.51)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fang, L3
Appenroth, D3
Decker, M3
Kiehntopf, M1
Lupp, A1
Peng, S1
Fleck, C3
Zhang, Y2
Lehmann, J2
Jumpertz, S1
Mohr, K1
Tränkle, C1
Jiang, L1
Huang, M1
Xu, S1
Wang, Y1
An, P1
Feng, C1
Chen, X1
Wei, X1
Han, Y2
Wang, Q1
Zhang, Z1
Chen, R1
An, W1
Wang, C1
Liao, G1
Dong, X1
Bi, A1
Yin, Z1
Luo, L1
Misik, J1
Korabecny, J1
Nepovimova, E1
Kracmarova, A1
Kassa, J1
Liu, JM1
Wu, PF1
Rao, J1
Zhou, J1
Shen, ZC1
Luo, H1
Huang, JG1
Liang, X1
Long, LH1
Xie, QG1
Jiang, FC1
Wang, F1
Chen, JG1
Schott, Y1
Kim, DH2
Park, SJ1
Kim, JM1
Jeon, SJ1
Cho, YW1
Son, KH1
Lee, HJ1
Moon, JH1
Cheong, JH1
Ko, KH1
Ryu, JH1
Zhao, Q2
Matsumoto, K2
Tsuneyama, K1
Tanaka, K1
Li, F1
Shibahara, N1
Miyata, T1
Yokozawa, T1
Mishima, K1
Egashira, N1
Matsumoto, Y1
Iwasaki, K1
Fujiwara, M1
Werber, EA1
Gandelman-Marton, R1
Klein, C1
Rabey, JM1
Darreh-Shori, T1
Hellström-Lindahl, E2
Flores-Flores, C1
Guan, ZZ1
Soreq, H1
Nordberg, A2
Rispoli, V1
Rotiroti, D1
Carelli, V1
Liberatore, F1
Scipione, L1
Marra, R1
Giorgioni, G1
Di Stefano, A1
Sabolek, HR1
Bunce, JG1
Chrobak, JJ1
Simard, M1
van Reekum, R1
Xu, Z1
Zheng, H1
Law, SL1
Dong So, D1
Xue, H1
Muñoz-Torrero, D1
Camps, P1
Lyketsos, CG1
Colenda, CC1
Beck, C1
Blank, K1
Doraiswamy, MP1
Kalunian, DA1
Yaffe, K1
Murakami, Y1
Tohda, M1
Obi, R1
Shimada, Y1
Davis, KL1
Powchik, P1
Siegfried, KR1
Sampalmieri, M1
Troiani, MP1
Servi, M1
Talwalker, S2
Overall, JE1
Srirama, MK1
Gracon, SI2
Kumar, V1
Goldstein, MZ1
Doraiswamy, PM1
Sternon, J1
Zemlan, FP1
Schneider, LS2
Rabins, PV1
Whitehouse, PJ1
Peskind, ER1
Amberla, K1
Shigeta, M1
Lundqvist, H1
Viitanen, M1
Johansson, M1
Andersson, J1
Hartvig, P1
Lilja, A1
Långström, B1
Winblad, B1
Lacomblez, L1
Trabucchi, M1
Farlow, M1
Hershey, LA1
Lewis, KW1
Sadowsky, CH1
Dolan-Ureno, J1
Hannington-Kiff, JG1

Reviews

10 reviews available for tacrine and Cognition Disorders

ArticleYear
The acetylcholinesterase inhibitors for treatment of cognitive and behavioral symptoms in dementia with Lewy bodies.
    The Journal of neuropsychiatry and clinical neurosciences, 2004,Fall, Volume: 16, Issue:4

    Topics: Aged; Basal Ganglia Diseases; Behavior; Cholinesterase Inhibitors; Clinical Trials as Topic; Cogniti

2004
Dimeric and hybrid anti-Alzheimer drug candidates.
    Current medicinal chemistry, 2006, Volume: 13, Issue:4

    Topics: Alzheimer Disease; Aminoquinolines; Animals; Binding Sites; Cholinesterase Inhibitors; Cognition Dis

2006
Tacrine.
    Lancet (London, England), 1995, Mar-11, Volume: 345, Issue:8950

    Topics: Alzheimer Disease; Brain; Clinical Trials as Topic; Cognition Disorders; Double-Blind Method; Drug I

1995
Pharmacodynamic and early clinical studies with velnacrine.
    Acta neurologica Scandinavica. Supplementum, 1993, Volume: 149

    Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Double-Blind Method; Female; Huma

1993
Advances in pharmacotherapy for decline of memory and cognition in patients with Alzheimer's disease.
    Psychiatric services (Washington, D.C.), 1996, Volume: 47, Issue:3

    Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Cognition Disorders; Humans; Memory Disorders

1996
New therapeutic approaches to Alzheimer's disease.
    The Journal of clinical psychiatry, 1996, Volume: 57 Suppl 14

    Topics: Alzheimer Disease; Antioxidants; Carbamates; Cholinergic Agents; Cholinesterase Inhibitors; Cognitio

1996
Developing treatment guidelines for Alzheimer's disease and other dementias.
    The Journal of clinical psychiatry, 1996, Volume: 57 Suppl 14

    Topics: Alzheimer Disease; Antipsychotic Agents; Behavior Therapy; Cognition Disorders; Dementia; Humans; Me

1996
Pharmacologic approaches to cognitive deficits in Alzheimer's disease.
    The Journal of clinical psychiatry, 1998, Volume: 59 Suppl 9

    Topics: Alzheimer Disease; Antioxidants; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Diso

1998
New therapeutic approaches to cognitive impairment.
    The Journal of clinical psychiatry, 1998, Volume: 59 Suppl 11

    Topics: Aged; Alzheimer Disease; Antioxidants; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; D

1998
An economic perspective on Alzheimer's disease.
    Journal of geriatric psychiatry and neurology, 1999,Spring, Volume: 12, Issue:1

    Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Combi

1999

Trials

6 trials available for tacrine and Cognition Disorders

ArticleYear
The clinical use of P300 event related potentials for the evaluation of cholinesterase inhibitors treatment in demented patients.
    Journal of neural transmission (Vienna, Austria : 1996), 2003, Volume: 110, Issue:6

    Topics: Acetylcholine; Aged; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Cognition Disorders; De

2003
Pharmacodynamic and early clinical studies with velnacrine.
    Acta neurologica Scandinavica. Supplementum, 1993, Volume: 149

    Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Double-Blind Method; Female; Huma

1993
Cardinal features of cognitive dysfunction in Alzheimer's disease: a factor-analytic study of the Alzheimer's Disease Assessment Scale.
    Journal of geriatric psychiatry and neurology, 1996, Volume: 9, Issue:1

    Topics: Aged; Alzheimer Disease; Cognition Disorders; Dose-Response Relationship, Drug; Drug Administration

1996
The cardinal features of cognitive and noncognitive dysfunction and the differential efficacy of tacrine in Alzheimer's disease patients.
    Journal of biopharmaceutical statistics, 1996, Volume: 6, Issue:4

    Topics: Aged; Alzheimer Disease; Cognition; Cognition Disorders; Double-Blind Method; Female; Humans; Male;

1996
Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial. The Mentane Study Group.
    Journal of neural transmission (Vienna, Austria : 1996), 1996, Volume: 103, Issue:8-9

    Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; D

1996
A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.
    JAMA, 1992, Nov-11, Volume: 268, Issue:18

    Topics: Alzheimer Disease; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Mental Status Sch

1992

Other Studies

24 other studies available for tacrine and Cognition Disorders

ArticleYear
NO-donating tacrine hybrid compounds improve scopolamine-induced cognition impairment and show less hepatotoxicity.
    Journal of medicinal chemistry, 2008, Dec-25, Volume: 51, Issue:24

    Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Chemistry, Pharmaceutical; Cognition; Cognition Di

2008
Hybrid molecules from xanomeline and tacrine: enhanced tacrine actions on cholinesterases and muscarinic M1 receptors.
    Journal of medicinal chemistry, 2010, Mar-11, Volume: 53, Issue:5

    Topics: Acetylcholinesterase; Animals; Butyrylcholinesterase; Central Nervous System Agents; Cholinesterase

2010
Bis(propyl)-cognitin Prevents β-amyloid-induced Memory Deficits as Well as Synaptic Formation and Plasticity Impairments via the Activation of PI3-K Pathway.
    Molecular neurobiology, 2016, Volume: 53, Issue:6

    Topics: Amyloid beta-Peptides; Animals; Cognition Disorders; Dendrites; Hippocampus; Long-Term Potentiation;

2016
A novel acetylcholinesterase inhibitor and calcium channel blocker SCR-1693 improves Aβ25-35-impaired mouse cognitive function.
    Psychopharmacology, 2016, Volume: 233, Issue:4

    Topics: Amyloid beta-Peptides; Animals; Calcium Channel Blockers; Cell Line, Tumor; CHO Cells; Cholinesteras

2016
Effects of novel tacrine-related cholinesterase inhibitors in the reversal of 3-quinuclidinyl benzilate-induced cognitive deficit in rats--Is there a potential for Alzheimer's disease treatment?
    Neuroscience letters, 2016, Jan-26, Volume: 612

    Topics: Alzheimer Disease; Animals; Avoidance Learning; Cholinesterase Inhibitors; Cognition Disorders; Done

2016
ST09, a Novel Thioester Derivative of Tacrine, Alleviates Cognitive Deficits and Enhances Glucose Metabolism in Vascular Dementia Rats.
    CNS neuroscience & therapeutics, 2016, Volume: 22, Issue:3

    Topics: Acetylcholinesterase; Animals; Apoptosis; Cell Line, Transformed; Cerebral Cortex; Cognition Disorde

2016
Investigation into the in vivo effects of five novel tacrine/ferulic acid and beta-carboline derivatives on scopolamine-induced cognitive impairment in rats using radial maze paradigm.
    Arzneimittel-Forschung, 2010, Volume: 60, Issue:6

    Topics: Animals; Carbolines; Cognition; Cognition Disorders; Coumaric Acids; Female; Maze Learning; Rats; Ra

2010
Cognitive dysfunctions induced by a cholinergic blockade and Aβ 25-35 peptide are attenuated by salvianolic acid B.
    Neuropharmacology, 2011, Volume: 61, Issue:8

    Topics: Amyloid beta-Peptides; Animals; Animals, Newborn; Benzofurans; Cholinergic Antagonists; Cholinestera

2011
Diabetes-induced central cholinergic neuronal loss and cognitive deficit are attenuated by tacrine and a Chinese herbal prescription, kangen-karyu: elucidation in type 2 diabetes db/db mice.
    Journal of pharmacological sciences, 2011, Volume: 117, Issue:4

    Topics: Animals; Brain; Cholinergic Neurons; Cognition Disorders; Diabetes Mellitus, Experimental; Diabetes

2011
Involvement of reduced acetylcholine release in Delta9-tetrahydrocannabinol-induced impairment of spatial memory in the 8-arm radial maze.
    Life sciences, 2002, Dec-20, Volume: 72, Issue:4-5

    Topics: Acetylcholine; Animals; Cerebral Cortex; Cholinesterase Inhibitors; Cognition Disorders; Dronabinol;

2002
Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients.
    Journal of neurochemistry, 2004, Volume: 88, Issue:5

    Topics: Acetylcholinesterase; Aged; Alternative Splicing; Alzheimer Disease; Blotting, Western; Carbamates;

2004
Choline pivaloyl esters improve in rats cognitive and memory performances impaired by scopolamine treatment or lesions of the nucleus basalis of Meynert.
    Neuroscience letters, 2004, Feb-19, Volume: 356, Issue:3

    Topics: Acetylcholinesterase; Analysis of Variance; Animals; Basal Nucleus of Meynert; Cell Count; Choline;

2004
Intraseptal tacrine can enhance memory in cognitively impaired young rats.
    Neuroreport, 2004, Jan-19, Volume: 15, Issue:1

    Topics: Age Factors; Animals; Cognition Disorders; Dose-Response Relationship, Drug; Female; Injections, Int

2004
Effects of a memory enhancing peptide on cognitive abilities of brain-lesioned mice: additivity with huperzine A and relative potency to tacrine.
    Journal of peptide science : an official publication of the European Peptide Society, 2006, Volume: 12, Issue:1

    Topics: Alkaloids; Animals; Avoidance Learning; Behavior, Animal; Brain Diseases; Cognition Disorders; Disea

2006
Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease.
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2006, Volume: 14, Issue:7

    Topics: Aged; Alkaloids; Alzheimer Disease; Brain; Caregivers; Cholinesterase Inhibitors; Cognition Disorder

2006
Chotosan, a kampo formula, ameliorates chronic cerebral hypoperfusion-induced deficits in object recognition behaviors and central cholinergic systems in mice.
    Journal of pharmacological sciences, 2007, Volume: 103, Issue:4

    Topics: Acetylcholinesterase; Actins; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain Ischemia; Cere

2007
Tacrine approved for cognitive deficits in Alzheimer's disease.
    The Nurse practitioner, 1994, Volume: 19, Issue:1

    Topics: Alzheimer Disease; Cognition Disorders; Drug Costs; Humans; Tacrine

1994
[Use of cholinesterase inhibitors in Alzheimer disease].
    La Clinica terapeutica, 1993, Volume: 143, Issue:6

    Topics: Acetylcholine; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Female; Humans; Ma

1993
Tacrine for Alzheimer's disease.
    The Medical letter on drugs and therapeutics, 1993, Sep-17, Volume: 35, Issue:905

    Topics: Alzheimer Disease; Animals; Clinical Trials as Topic; Cognition Disorders; Drug Interactions; Humans

1993
[Melatonin, methadone, tacrine, vitamin K antagonists and low-molecular-weight heparin].
    Revue medicale de Bruxelles, 1996, Volume: 17, Issue:4

    Topics: Aged; Anticoagulants; Cholinesterase Inhibitors; Circadian Rhythm; Cognition Disorders; Heroin Depen

1996
Pharmacoeconomics of dementia.
    Alzheimer disease and associated disorders, 1997, Volume: 11 Suppl 5

    Topics: Alzheimer Disease; Chronic Disease; Clinical Trials, Phase III as Topic; Cognition Disorders; Costs

1997
Long-term tacrine treatment in three mild Alzheimer patients: effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities.
    Alzheimer disease and associated disorders, 1998, Volume: 12, Issue:3

    Topics: Aged; Alzheimer Disease; Blood Glucose; Brain; Cognition Disorders; Dose-Response Relationship, Drug

1998
[Drug therapy strategies in Alzheimer's disease].
    La Revue du praticien, 1998, Nov-01, Volume: 48, Issue:17

    Topics: Aggression; Alzheimer Disease; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Car

1998
Tetrahydroaminoacridine and the central anticholinergic syndrome.
    Lancet (London, England), 1987, Apr-11, Volume: 1, Issue:8537

    Topics: Aged; Aminoacridines; Anesthesia, General; Cognition Disorders; Confusion; Drug Interactions; Humans

1987